Profound Medical Corp. (PROF) Company Overview

What does Profound Medical do?

Profound Medical Corp. is a commercial-stage medical-device company focused on interventional magnetic resonance imaging, or iMRI. Its central idea is that an MRI scanner can do more than diagnose disease: it can guide, monitor, and confirm therapy in real time. Profound trades as PROF on Nasdaq and PRN on the Toronto Stock Exchange, and its operating story is built primarily around two therapeutic platforms, TULSA-PRO and Sonalleve.

Which products define the business?

The flagship TULSA-PRO platform combines directional ultrasound, a water-cooled urethral applicator, rectal protection, MRI thermometry, and closed-loop software. The treatment temperature is adjusted continuously based on real-time imaging feedback. This creates a precision proposition that differs from conventional open or robotic surgery, radiation, and less-customizable ablation approaches.

How does Profound Medical make money?

Profound uses a hybrid medical-device model. It earns one-time capital revenue from selling or leasing systems, then earns recurring non-capital revenue from procedure-specific disposable devices and extended-warranty services. In the United States, the system and one-time-use devices are charged separately. Outside North America, both TULSA-PRO and Sonalleve generally follow a similar capital-plus-disposable model, although Sonalleve carries more limited recurring service revenue.

Which revenue stream is most important?

Capital sales currently matter because Profound is still building the network. Each placement can produce a large but uneven revenue contribution, which makes quarter-to-quarter forecasting difficult. Recurring revenue is more valuable analytically because it reflects procedure volume, disposables consumed, service contracts, and the installed base becoming productive. In Q1 2026, recurring non-capital revenue rose to $2.474 million from $1.801 million a year earlier, while capital equipment revenue increased to $2.863 million from $0.820 million.

How does the economic flywheel work?

What does the latest quarter show?

The quarter ended March 31, 2026 showed the strongest combination yet of rapid growth, high gross margin, and lower operating expense. Revenue doubled to $5.337 million from $2.621 million, gross profit rose to $3.832 million from $1.853 million, and gross margin edged up to 72% from 71%. Operating expenses declined 9% to $11.853 million, producing an operating loss of $8.021 million versus $11.166 million a year earlier.

Why does the margin signal matter?

The key tension is clear: Profound has strong gross economics but insufficient scale. Q1 2026 R&D expense was $5.262 million and SG&A was $6.591 million, compared with only $3.832 million of gross profit. The operating model can improve rapidly if procedure volumes and system placements rise without a matching increase in overhead, but the current cost base still requires continued cash funding.

The latest official Q1 2026 earnings release and quarterly Form 10-Q also show why revenue forecasting remains difficult: six systems had shipped by quarter-end but were not yet installed, so shipment, installation, acceptance, and revenue recognition can fall in different periods.

Which adoption KPIs matter most for TULSA-PRO?

For an early commercial medical-device company, revenue alone can hide the mechanics of adoption. Profound’s most useful operating indicators are installed systems, systems shipped but not installed, the qualified sales pipeline, procedure volume per active site, recurring revenue, payer coverage, and the mix of disease types treated. Together, these metrics show whether TULSA-PRO is becoming a repeatable clinical platform rather than a collection of isolated capital sales.

Is utilization improving at mature sites?

The INDEX20 is particularly valuable because it separates mature-site utilization from the noise created when new systems enter the denominator. Average procedures per quarter rose from 7.1 in Q1 2025 to 11.3 in Q1 2026. Sequential growth was 10% in the latest quarter, following 20% in Q4 2025. Higher utilization should lift recurring disposable revenue and strengthen the economic case for hospitals considering a system purchase.

What patient mix reveals about platform flexibility

What strategic turning points shaped Profound Medical?

Profound’s current position is the result of a long shift from technology development toward commercial execution. The most important milestones are not corporate trivia; they explain why the company now has regulatory clearance, a growing clinical network, procedural reimbursement infrastructure, and randomized evidence that may support broader adoption.

1. 2015–2018
   Development and the TACT pivotal study established the clinical and regulatory foundation for MRI-guided transurethral ultrasound ablation.
2. August 2019
   The FDA cleared TULSA-PRO through the 510(k) pathway for transurethral ultrasound ablation of prostate tissue, opening the U.S. market.
3. October 2019
   Profound began trading on Nasdaq under PROF, broadening capital-market access and investor visibility.
4. 2023–2025
   CMS and AMA coding developments, including Category I CPT codes effective January 1, 2025, improved the administrative foundation for reimbursement.
5. 2025
   The installed base reached 78 by year-end, annual revenue rose to $16.1 million, and a mature-site procedure index began demonstrating utilization growth.
6. March 2026
   The CAPTAIN randomized trial met its primary safety endpoint versus robotic radical prostatectomy, strengthening the evidence base for intermediate-risk prostate cancer.
7. May 2026
   Humana coverage was announced, adding to the payer-access momentum that can influence both patient flow and hospital purchasing decisions.

Why CAPTAIN may be the most important inflection point

The CAPTAIN trial announcement reported superiority on the prespecified primary safety endpoint, focused on preservation of erectile function and urinary continence, in men with organ-confined intermediate-risk prostate cancer. That is strategically significant because robotic radical prostatectomy is an established standard of care. A randomized comparison can influence physician confidence, payer decisions, guideline discussions, and patient preference more meaningfully than a single-arm study.

What gives Profound Medical a competitive advantage?

Profound’s potential moat is a system of interlocking capabilities rather than one simple patent or brand claim. The combination includes MRI thermometry, directional ultrasound, robotic control, treatment-planning software, urethral and rectal cooling, disposable devices, clinical workflow expertise, regulatory clearances, trial evidence, and a growing network of experienced sites. Replicating the full package requires engineering, clinical validation, manufacturing, physician training, and reimbursement work.

Where differentiation is strongest

The company’s official platform overview emphasizes the ability to customize treatment boundaries instead of applying a single standardized lesion. That flexibility matters because prostate disease varies by location, grade, volume, prior treatment, and coexistence with BPH. It also creates a broad procedural use case, as shown by the Q4 2025 patient mix and treatment-intent data.

What keeps the moat from being fully established?

The moat remains incomplete because procedure volumes are still modest, profitability has not been achieved, and clinical adoption can be slowed by workflow complexity. MRI time is valuable, hospitals must coordinate urology and radiology teams, and physicians need training. A compelling technology becomes durable only when it is embedded in routine practice, supported by payers, and economically attractive for providers.

Who are Profound Medical’s competitors?

Profound competes less against one identical device than against a set of established treatment pathways. For localized prostate cancer, the most important alternatives include robotic radical prostatectomy, radiation therapy, active surveillance, cryotherapy, high-intensity focused ultrasound, and other focal-ablation approaches. For BPH, the competitive set includes medications, transurethral resection, laser procedures, water-vapor therapies, implants, and robotic waterjet ablation. The practical competitor is often the current care pathway already familiar to physicians, hospitals, and payers.

How should market position be assessed?

Profound should not yet be described as dominant. Its installed base of 80 systems at March 31, 2026 is meaningful for an emerging category but small compared with mature surgical and radiation infrastructure. The better framing is that Profound has a differentiated technology with expanding evidence and a growing reference network. Its opportunity is to become a recognized choice within a very large prostate-care market, not necessarily to replace every existing modality.

How financially strong is Profound Medical?

Profound is financially liquid but not self-funding. Cash was $50.295 million at March 31, 2026, down from $59.723 million at December 31, 2025. Net cash used in operating activities was $8.584 million in Q1 2026, compared with $8.283 million in Q1 2025. The company stated that existing cash plus product and service sales should fund operating expenses and capital expenditures for at least 12 months from issuance of the Q1 statements.

What does the annual baseline show?

The 2025 Form 10-K filing and full-year 2025 results show that gross margin is not the problem. The challenge is the gap between gross profit and the cost of R&D, clinical evidence, sales, training, reimbursement support, and corporate infrastructure.

Who owns Profound Medical stock, and how is it governed?

Profound has one class of common shares rather than a dual-class founder-control structure. As of May 7, 2026, 36,337,637 common shares were outstanding. The 2026 management circular shows that Chief Executive Officer and Chairman Arun Menawat beneficially owned or controlled 658,660 common shares, equal to 1.81%, plus 1,024,092 options and units. Economic control is therefore dispersed, but management incentives include a meaningful equity component.

What do incentives emphasize?

The 2026 management information circular describes a compensation framework combining salary, annual bonuses, options, and restricted share units. Quantitative objectives include revenue targets, while departmental and individual goals can include product development, productivity, commercial execution, and long-term strategic guidance. This is appropriate for a company where near-term revenue growth, clinical milestones, and platform development all matter, but it also requires investors to watch dilution and the relationship between equity awards and value creation.

What opportunities and risks could change the outlook?

Profound’s upside depends on crossing several adoption thresholds at once: more installed systems, higher procedures per site, broader payer coverage, stronger randomized data, smoother hospital workflows, and rising recurring revenue. The downside is that any one of these links can slow the flywheel. Medical-device adoption is rarely a simple function of clinical promise; it also depends on budgets, training, scheduling, reimbursement, referrals, and proof that providers can earn an acceptable return on their MRI capacity.

Which filing risks are most material?

• Adoption risk: clinicians and hospitals may continue choosing established surgery, radiation, HIFU, or BPH procedures despite favorable TULSA evidence.
• Reimbursement risk: coding does not guarantee consistent coverage or adequate payment across payers, diagnoses, and sites of service.
• Clinical and regulatory risk: adverse outcomes, trial results, labeling changes, product issues, or regulatory requirements could slow commercialization.
• Capital-intensity risk: hospitals may delay purchases because MRI suites are expensive, heavily utilized, and operationally complex.
• Manufacturing and supply risk: specialized systems and disposables require dependable quality, suppliers, inventory, and service support.
• Financing and dilution risk: continued losses and cash use may require additional capital before the business reaches break-even.
• Forecasting risk: a small number of system sales can materially shift quarterly revenue based on shipment, installation, acceptance, and recognition timing.

The company’s reimbursement information appropriately notes that payer policies vary and must be verified. That caveat is central to the business model: clinical demand may exist before payment pathways become predictable, creating a gap between patient interest and realized revenue.

Why does Profound Medical matter for valuation?

A conventional mature-company valuation is not sufficient for Profound because current earnings are deeply negative while the product gross margin is high. The key question is whether a growing installed base can create enough recurring procedures to produce operating leverage before cash resources become constrained. A DCF model therefore needs explicit assumptions for system placements, installation timing, procedures per site, disposable revenue per procedure, capital-system pricing, gross margin, R&D, commercial spending, and future financing.

Which variables drive a DCF most?

Comparable-company analysis also requires care. Profound is part capital-equipment vendor, part recurring-disposable model, and part emerging procedural platform. Revenue multiples may be more informative than earnings multiples today, but they should be interpreted alongside gross margin, growth, recurring mix, cash burn, and clinical maturity. A high growth rate from a small base does not automatically imply low risk; adoption and financing assumptions dominate the outcome.

What is the key takeaway from Profound Medical analysis?

Profound Medical is building a differentiated MRI-guided therapy platform around a clear clinical proposition: precise, customized prostate-tissue ablation without an incision or radiation, with real-time control intended to preserve important function. The technology has progressed beyond concept stage. TULSA-PRO is FDA cleared, the installed base reached 80 systems by March 31, 2026, mature-site procedure volume rose 59% year over year, Q1 revenue increased 104%, gross margin was 72%, and the CAPTAIN randomized trial met its primary safety endpoint.

At the same time, Profound remains an early-scale company. Q1 operating expenses of $11.853 million were more than three times gross profit, operating cash use was $8.584 million, and quarterly revenue remains sensitive to a small number of capital-system transactions. The company must convert a 110-system qualified pipeline into installations, turn installations into repeat procedures, expand payer coverage, and prove that hospitals can integrate the workflow economically.